{"id":"https://openalex.org/W2103477598","doi":"https://doi.org/10.2215/cjn.04371206","title":"Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease","display_name":"Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease","publication_year":2007,"publication_date":"2007-10-17","ids":{"openalex":"https://openalex.org/W2103477598","doi":"https://doi.org/10.2215/cjn.04371206","mag":"2103477598","pmid":"https://pubmed.ncbi.nlm.nih.gov/17942759"},"language":"en","primary_location":{"id":"doi:10.2215/cjn.04371206","doi":"https://doi.org/10.2215/cjn.04371206","is_oa":false,"landing_page_url":"https://doi.org/10.2215/cjn.04371206","pdf_url":null,"source":{"id":"https://openalex.org/S184267533","display_name":"Clinical Journal of the American Society of Nephrology","issn_l":"1555-9041","issn":["1555-9041","1555-905X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Journal of the American Society of Nephrology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5106691980","display_name":"James Shepherd","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":true,"raw_author_name":"James Shepherd","raw_affiliation_strings":["Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK. jshepherd@gri-biochem.org.uk","**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK. jshepherd@gri-biochem.org.uk","institution_ids":["https://openalex.org/I7882870"]},{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077848934","display_name":"John J.P. Kastelein","orcid":"https://orcid.org/0000-0003-2018-4532","observed_orcids":["https://orcid.org/0000-0003-2018-4532"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"John J.P. Kastelein","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048484359","display_name":"Vera Bittner","orcid":"https://orcid.org/0000-0001-9456-850X","observed_orcids":["https://orcid.org/0000-0001-9456-850X"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Vera Bittner","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078294568","display_name":"PRAKASH C. DEEDWANIA","orcid":"https://orcid.org/0000-0002-5652-9347","observed_orcids":["https://orcid.org/0000-0002-5652-9347"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Prakash Deedwania","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029771378","display_name":"Andrei Breazna","orcid":"https://orcid.org/0000-0001-7478-2293","observed_orcids":["https://orcid.org/0000-0001-7478-2293"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Andrei Breazna","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stephen Dobson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Stephen Dobson","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108082618","display_name":"Daniel J. Wilson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Daniel J. Wilson","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109278860","display_name":"Andrea L. Zuckerman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Andrea Zuckerman","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008209592","display_name":"NANETTE KASS WENGER","orcid":"https://orcid.org/0000-0003-0990-6151","observed_orcids":["https://orcid.org/0000-0003-0990-6151"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4210147977","display_name":"VA Central California Health Care System","ror":"https://ror.org/03wjr6873","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210125474","https://openalex.org/I4210147977"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["GB","NL","US"],"is_corresponding":false,"raw_author_name":"Nanette K. Wenger","raw_affiliation_strings":["**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"**Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York; *Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom; Accepted July 29, 2007; E-mail: [email\u00a0protected]; Fax: +44-141-5531703; Received December 22, 2006; \u00a7Cardiology Division, VA Central California Healthcare System and UCSF School of Medicine, Fresno, California; \u00b6Scientific Solutions, Envision Pharma Ltd., Horsham, United Kingdom; \u2016Global Research and Development; \u2020Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; \u2020\u2020Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; \u2021Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5106691980"],"corresponding_institution_ids":["https://openalex.org/I150468666","https://openalex.org/I180670191","https://openalex.org/I180857899","https://openalex.org/I2802928900","https://openalex.org/I32389192","https://openalex.org/I4210147977","https://openalex.org/I4210151833","https://openalex.org/I7882870","https://openalex.org/I887064364"],"apc_list":null,"apc_paid":null,"fwci":16.2918,"has_fulltext":false,"cited_by_count":275,"citation_normalized_percentile":{"value":0.99356476,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"2","issue":"6","first_page":"1131","last_page":"1139"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9452999830245972,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9452999830245972,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.0494999997317791,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atorvastatin","display_name":"atorvastatin","score":1.0},{"id":"https://openalex.org/keywords/intensive-lipid-lowering","display_name":"intensive lipid lowering","score":0.8870000243186951},{"id":"https://openalex.org/keywords/renal-function","display_name":"renal function","score":0.8849999904632568},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate","display_name":"estimated glomerular filtration rate","score":0.9449999928474426},{"id":"https://openalex.org/keywords/coronary-artery-disease","display_name":"coronary artery disease","score":0.9629999995231628},{"id":"https://openalex.org/keywords/statin-dose","display_name":"statin dose","score":0.6240000128746033},{"id":"https://openalex.org/keywords/renal-protection","display_name":"renal protection","score":0.9620000123977661},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.5210000276565552},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.42899999022483826}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9346587657928467},{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.9280434846878052},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.8100045919418335},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.6011490821838379},{"id":"https://openalex.org/C2780306776","wikidata":"https://www.wikidata.org/wiki/Q426660","display_name":"Creatinine","level":2,"score":0.585822582244873},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5477442741394043},{"id":"https://openalex.org/C3018906752","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Coronary heart disease","level":2,"score":0.5369261503219604},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.5029458403587341},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4441390633583069}],"mesh":[{"descriptor_ui":"D000069059","descriptor_name":"Atorvastatin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005919","descriptor_name":"Glomerular Filtration Rate","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007668","descriptor_name":"Kidney","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007668","descriptor_name":"Kidney","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D007674","descriptor_name":"Kidney Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D008076","descriptor_name":"Cholesterol, HDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.2215/cjn.04371206","doi":"https://doi.org/10.2215/cjn.04371206","is_oa":false,"landing_page_url":"https://doi.org/10.2215/cjn.04371206","pdf_url":null,"source":{"id":"https://openalex.org/S184267533","display_name":"Clinical Journal of the American Society of Nephrology","issn_l":"1555-9041","issn":["1555-9041","1555-905X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Journal of the American Society of Nephrology","raw_type":"journal-article"},{"id":"pmid:17942759","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17942759","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical journal of the American Society of Nephrology : CJASN","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.601.4949","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.601.4949","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://cjasn.asnjournals.org/content/2/6/1131.full.pdf","raw_type":"text"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/b93d0355-06d9-47aa-8bb7-60afa9b64f2f","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/effect-of-intensive-lipid-lowering-with-atorvastatin-on-renal-function-in-patients-with-coronary-heart-disease-the-treating-to-new-targets-tnt-study(b93d0355-06d9-47aa-8bb7-60afa9b64f2f).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical journal of the American Society of Nephrology, 2(6), 1131 - 1139. American Society of Nephrology","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:boris.unibe.ch:24552","doi":null,"is_oa":false,"landing_page_url":"https://boris.unibe.ch/24552/","pdf_url":null,"source":{"id":"https://openalex.org/S4306401747","display_name":"BORIS (University Library Bern)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210103840","host_organization_name":"Nakuru County Council","host_organization_lineage":["https://openalex.org/I4210103840"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/e4cbc58e-90a3-4920-9b05-0d6132e69d0d","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/e4cbc58e-90a3-4920-9b05-0d6132e69d0d","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Shepherd, J, Kastelein, J J P, Bittner, V, Deedwania, P, Breazna, A, Dobson, S, Wilson, D J, Zuckerman, A & Wenger, N K 2007, 'Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study', Clinical journal of the American Society of Nephrology, vol. 2, no. 6, pp. 1131-1139. https://doi.org/10.2215/CJN.04371206","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320306230","display_name":"American Heart Association","ror":"https://ror.org/013kjyp64"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":47,"referenced_works":["https://openalex.org/W1502524639","https://openalex.org/W1550111394","https://openalex.org/W1971041473","https://openalex.org/W1971056977","https://openalex.org/W1974017647","https://openalex.org/W1976878146","https://openalex.org/W1981155050","https://openalex.org/W1985992748","https://openalex.org/W1998747783","https://openalex.org/W2002384775","https://openalex.org/W2018901137","https://openalex.org/W2027441714","https://openalex.org/W2029421987","https://openalex.org/W2031185570","https://openalex.org/W2038261200","https://openalex.org/W2043253248","https://openalex.org/W2055864845","https://openalex.org/W2078946004","https://openalex.org/W2082069148","https://openalex.org/W2083911580","https://openalex.org/W2084671094","https://openalex.org/W2099882339","https://openalex.org/W2100800328","https://openalex.org/W2106343349","https://openalex.org/W2107295258","https://openalex.org/W2117848894","https://openalex.org/W2118992949","https://openalex.org/W2120309176","https://openalex.org/W2124764590","https://openalex.org/W2132627628","https://openalex.org/W2133275623","https://openalex.org/W2137854025","https://openalex.org/W2139168645","https://openalex.org/W2145632027","https://openalex.org/W2146311281","https://openalex.org/W2146427394","https://openalex.org/W2150144996","https://openalex.org/W2152135127","https://openalex.org/W2157214027","https://openalex.org/W2159449551","https://openalex.org/W2322699894","https://openalex.org/W2460256673","https://openalex.org/W2562329777","https://openalex.org/W2581940450","https://openalex.org/W2621213683","https://openalex.org/W4249825849","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W4243172360","https://openalex.org/W2002392903","https://openalex.org/W2078198126","https://openalex.org/W2262348748","https://openalex.org/W169039994","https://openalex.org/W2355002597","https://openalex.org/W2377849815","https://openalex.org/W2792746646","https://openalex.org/W2258996537","https://openalex.org/W2064446331"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVES:":[2],"Data":[3],"suggest":[4],"that":[5],"atorvastatin":[6,28],"may":[7,253],"be":[8,254],"nephroprotective.":[9],"This":[10],"subanalysis":[11],"of":[12,27,50,61,81,95,137,155],"the":[13,79,93,119,131,135,184,218],"Treating":[14],"to":[15,67,141,190,205],"New":[16],"Targets":[17],"study":[18],"investigated":[19],"how":[20],"intensive":[21],"lipid":[22],"lowering":[23],"with":[24,34,39,53,70,100,163,174,243,247],"80":[25,73,175,244],"mg":[26,36,165,176,245],"affects":[29],"renal":[30,102,227],"function":[31,228],"when":[32],"compared":[33,88],"10":[35,71,164,248],"in":[37,83,97,118,130,149,199,212,217,226,235],"patients":[38,52,202,215],"coronary":[40,54],"heart":[41,55],"disease.":[42],"DESIGN,":[43],"SETTING,":[44],"PARTICIPANTS,":[45],"&":[46],"MEASUREMENTS:":[47],"A":[48],"total":[49],"10,001":[51],"disease":[56],"and":[57,91,122,166,203],"LDL":[58],"cholesterol":[59],"levels":[60],"<130":[62],"mg/dl":[63],"were":[64],"randomly":[65],"assigned":[66],"double-blind":[68],"therapy":[69],"or":[72,192],"mg/d":[74],"atorvastatin.":[75],"Estimated":[76,232],"GFR":[77,107,151,188,233],"using":[78],"Modification":[80],"Diet":[82],"Renal":[84],"Disease":[85],"equation":[86],"was":[87,110,229,240],"at":[89,92,108],"baseline":[90,109],"end":[94,136],"follow-up":[96,138],"9656":[98],"participants":[99],"complete":[101],"data.":[103],"RESULTS:":[104],"Mean":[105],"estimated":[106,150,187],"65.6":[111],"+/-":[112,124,157,168],"11.4":[113],"ml/min":[114,126,159,170,195,208],"per":[115,127,160,171,196,209],"1.73":[116,128,161,172,197,210],"m2":[117,129,162,173,198,211],"10-mg":[120,219],"group":[121],"65.0":[123],"11.2":[125],"80-mg":[132,185],"group.":[133],"At":[134],"(median":[139],"time":[140],"final":[142],"creatinine":[143],"measurement":[144],"59.5":[145],"months),":[146],"mean":[147],"change":[148],"showed":[152],"an":[153],"increase":[154],"3.5":[156],"0.14":[158,169],"5.2":[167],"(P":[177],"<":[178,206],"0.0001":[179],"for":[180],"treatment":[181,237],"difference).":[182],"In":[183],"arm,":[186],"improved":[189,234],">":[191],"=":[193],"60":[194,207],"significantly":[200,213,241],"more":[201],"declined":[204],"fewer":[214],"than":[216,246],"arm.":[220],"CONCLUSIONS:":[221],"The":[222],"expected":[223],"5-yr":[224],"decline":[225],"not":[230],"observed.":[231],"both":[236],"groups":[238],"but":[239],"greater":[242],"mg,":[249],"suggesting":[250],"this":[251],"benefit":[252],"dosage":[255],"related.":[256]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":15},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":16},{"year":2014,"cited_by_count":33},{"year":2013,"cited_by_count":17},{"year":2012,"cited_by_count":26}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}